ELOXX PHARMACEUTICALS, INC. Comprehensive Income
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Comprehensive Income of -$66.73 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2022-03-30
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-12-31 was -$12.09M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-09-30 was -$9.88M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-06-30 was -$36.06M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-03-31 was -$8.69M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$66.73M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$34.59M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$50.86M.
- ELOXX PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$47.19M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 180 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 183 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 186 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 189 month |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$21.98M derived: sum of 2 quarters · filed 2022-03-30 | -$58.03M derived: sum of 3 quarters · filed 2022-03-30 | -$66.73M 10-K · filed 2022-03-30 | ||||
| 2021-09-30 | -$9.88M 10-Q · filed 2021-11-08 | -$45.94M derived: sum of 2 quarters · filed 2021-11-08 | -$54.64M 10-Q · filed 2021-11-08 | -$60.76M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2021-06-30 | -$36.06M 10-Q · filed 2021-08-16 | -$44.75M 10-Q · filed 2021-08-16 | -$50.88M derived: sum of 3 quarters · filed 2022-03-30 | -$57.51M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2021-03-31 | -$8.69M 10-Q · filed 2021-05-07 | -$14.82M derived: sum of 2 quarters · filed 2022-03-30 | -$21.45M derived: sum of 3 quarters · filed 2022-03-30 | -$29.39M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2020-12-31 | -$6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$12.76M derived: sum of 2 quarters · filed 2022-03-30 | -$20.70M derived: sum of 3 quarters · filed 2022-03-30 | -$34.59M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | -$6.63M 10-Q · filed 2021-11-08 | -$14.57M derived: sum of 2 quarters · filed 2021-11-08 | -$28.47M 10-Q · filed 2021-11-08 | -$40.09M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2020-06-30 | -$7.94M 10-Q · filed 2021-08-16 | -$21.84M 10-Q · filed 2021-08-16 | -$33.47M derived: sum of 3 quarters · filed 2022-03-30 | -$46.35M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2020-03-31 | -$13.90M 10-Q · filed 2021-05-07 | -$25.53M derived: sum of 2 quarters · filed 2022-03-30 | -$38.41M derived: sum of 3 quarters · filed 2022-03-30 | -$52.84M derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2019-12-31 | -$11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$24.51M derived: sum of 2 quarters · filed 2022-03-30 | -$38.94M derived: sum of 3 quarters · filed 2022-03-30 | -$50.86M 10-K · filed 2022-03-30 | ||||
| 2019-09-30 | -$12.89M 10-Q · filed 2020-11-06 | -$27.31M derived: sum of 2 quarters · filed 2020-11-06 | -$39.23M 10-Q · filed 2020-11-06 | -$53.26M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-06-30 | -$14.43M 10-Q · filed 2020-08-07 | -$26.34M 10-Q · filed 2020-08-07 | -$40.37M derived: sum of 3 quarters · filed 2021-03-12 | -$51.53M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | -$11.92M 10-Q · filed 2020-05-08 | -$25.94M derived: sum of 2 quarters · filed 2021-03-12 | -$37.10M derived: sum of 3 quarters · filed 2021-03-12 | -$50.51M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | -$14.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$25.19M derived: sum of 2 quarters · filed 2021-03-12 | -$38.59M derived: sum of 3 quarters · filed 2021-03-12 | -$47.19M 10-K · filed 2021-03-12 | ||||
| 2018-09-30 | -$11.16M 10-Q · filed 2019-11-06 | -$24.57M derived: sum of 2 quarters · filed 2019-11-06 | -$33.16M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | -$13.41M 10-Q · filed 2019-08-07 | -$22.00M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | -$8.59M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$23.62M 10-K · filed 2020-03-06 | |||||||
| 2017-03-31 | -$2.08M 10-Q · filed 2017-05-22 | -$2.88M derived: sum of 2 quarters · filed 2017-05-22 | -$3.82M 10-Q · filed 2017-05-22 | -$4.98M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2016-12-31 | -$805.61K 10-Q · filed 2017-02-10 | -$1.75M 10-Q · filed 2017-02-10 | -$2.91M derived: sum of 3 quarters · filed 2017-02-10 | -$6.00M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2016-09-30 | -$943.08K 10-Q · filed 2016-11-14 | -$2.10M derived: sum of 2 quarters · filed 2016-11-14 | -$5.19M derived: sum of 3 quarters · filed 2017-05-22 | -$9.06M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2016-06-30 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | -$4.25M derived: sum of 2 quarters · filed 2017-05-22 | -$8.12M derived: sum of 3 quarters · filed 2017-05-22 | -$8.45M 10-K · filed 2016-10-13 | ||||
| 2016-03-31 | -$3.09M 10-Q · filed 2017-05-22 | -$6.96M derived: sum of 2 quarters · filed 2017-05-22 | -$7.29M 10-Q · filed 2017-05-22 | -$8.99M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2015-12-31 | -$3.87M 10-Q · filed 2017-02-10 | -$4.20M 10-Q · filed 2017-02-10 | -$5.90M derived: sum of 3 quarters · filed 2017-02-10 | -$7.14M derived: sum of 4 quarters · filed 2017-02-10 | ||||
| 2015-09-30 | -$329.11K 10-Q · filed 2016-11-14 | -$2.03M derived: sum of 2 quarters · filed 2016-11-14 | -$3.27M derived: sum of 3 quarters · filed 2016-11-14 | -$14.03M derived: sum of 4 quarters · filed 2016-11-14 | ||||
| 2015-06-30 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | -$2.94M derived: sum of 2 quarters · filed 2016-10-13 | -$13.70M derived: sum of 3 quarters · filed 2016-10-13 | -$18.90M 10-K · filed 2016-10-13 | ||||
| 2015-03-31 | -$1.24M 10-Q · filed 2016-05-12 | -$12.00M derived: sum of 2 quarters · filed 2016-05-12 | -$17.20M 10-Q · filed 2016-05-12 | -$22.58M derived: sum of 4 quarters · filed 2016-10-13 | ||||
| 2014-12-31 | -$10.76M 10-Q · filed 2016-02-16 | -$15.96M 10-Q · filed 2016-02-16 | -$21.35M derived: sum of 3 quarters · filed 2016-10-13 | -$26.37M derived: sum of 4 quarters · filed 2016-10-13 | ||||
| 2014-09-30 | -$5.20M 10-Q · filed 2015-11-16 | -$10.58M derived: sum of 2 quarters · filed 2016-10-13 | -$15.61M derived: sum of 3 quarters · filed 2016-10-13 | -$17.25M derived: sum of 4 quarters · filed 2016-10-13 | ||||
| 2014-06-30 | -$5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | -$10.41M derived: sum of 2 quarters · filed 2016-10-13 | -$12.05M derived: sum of 3 quarters · filed 2016-10-13 | -$13.85M 10-K · filed 2016-10-13 | ||||
| 2014-03-31 | -$5.02M 10-Q · filed 2015-05-14 | -$6.66M derived: sum of 2 quarters · filed 2015-05-14 | -$8.47M 10-Q · filed 2015-05-14 | -$10.47M derived: sum of 4 quarters · filed 2015-10-09 | -$82.90M 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | -$1.64M 10-Q · filed 2015-02-17 | -$3.45M 10-Q · filed 2015-02-17 | -$5.44M derived: sum of 3 quarters · filed 2015-10-09 | -$6.43M derived: sum of 4 quarters · filed 2015-10-09 | -$77.87M 10-Q · filed 2014-02-14 | |||
| 2013-09-30 | -$1.81M 10-Q · filed 2014-11-14 | -$3.80M derived: sum of 2 quarters · filed 2015-10-09 | -$4.79M derived: sum of 3 quarters · filed 2015-10-09 | -$6.08M derived: sum of 4 quarters · filed 2015-10-09 | -$76.23M 10-Q · filed 2013-11-14 | |||
| 2013-06-30 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-09 | -$2.98M derived: sum of 2 quarters · filed 2015-10-09 | -$4.28M derived: sum of 3 quarters · filed 2015-10-09 | -$6.99M 10-K · filed 2015-10-09 | -$74.43M 10-K · filed 2013-09-11 | |||
| 2013-03-31 | -$986.72K 10-Q · filed 2014-05-09 | -$2.28M derived: sum of 2 quarters · filed 2014-05-09 | -$4.99M 10-Q · filed 2014-05-09 | -$6.60M derived: sum of 4 quarters · filed 2014-09-29 | ||||
| 2012-12-31 | -$1.29M 10-Q · filed 2014-02-14 | -$4.00M 10-Q · filed 2014-02-14 | -$5.61M derived: sum of 3 quarters · filed 2014-09-29 | -$7.09M derived: sum of 4 quarters · filed 2014-09-29 | ||||
| 2012-09-30 | -$2.71M 10-Q · filed 2013-11-14 | -$4.32M derived: sum of 2 quarters · filed 2014-09-29 | -$5.80M derived: sum of 3 quarters · filed 2014-09-29 | |||||
| 2012-06-30 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | -$3.09M derived: sum of 2 quarters · filed 2014-09-29 | -$6.69M 10-K · filed 2014-09-29 | |||||
| 2012-03-31 | -$1.48M 10-Q · filed 2013-05-15 | -$5.08M 10-Q · filed 2013-05-15 | ||||||
| 2011-06-30 | -$9.91M 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |